| |
|
|
|
|
|
 |
| |
|
Æ®¶ó¹Ö¿£Á¤ Tramingen Tab.
|
|
ÀϹÝÀǾàǰ | ºñ±Þ¿©
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
649701910
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
[ºñ±Þ¿©]
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
ºÐÈ«»öÀÇ ¿øÇüÁ¤Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
2Á¤/PTP |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 25¹Ð¸®±×·¥ |
2 Á¤ |
PTP |
8806497019103 |
8806497019110 |
|
|
| ÁÖ¼ººÐÄÚµå |
A04100ATB
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
¸Ö¹Ì¿¡ ÀÇÇÑ ¾îÁö·¯¿ò‧±¸Åä‧µÎÅëÀÇ ¿¹¹æ
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¼ºÀÎ : ¸Ö¹ÌÀÇ ¿¹¹æ¿¡´Â ½ÂÂ÷ 30ºÐ¿¡¼ 1½Ã°£Àü¿¡ 1ȸ 1Á¤À» º¹¿ëÇÑ´Ù. ¶Ç ÇÊ¿ä½Ã Ãß°¡º¹¿ëÇÒ °æ¿ì¿¡´Â 4½Ã°£ ÀÌ»ó °£°ÝÀ» µÎ°í º¹¿ëÇÑ´Ù.
1ÀÏ º¹¿ëȸ¼ö´Â 2ȸ¸¦ Çѵµ·Î ÇÑ´Ù.
|
| ±Ý±â |
15¼¼ ¹Ì¸¸ÀÇ ¼Ò¾Æ(ÇÁ·Î¸ÞŸÁø¿°·ù¸¦ ÇÔÀ¯ÇÏ´Â Á¦Á¦)
|
| ½ÅÁßÅõ¿© |
1) ¾àÀ¸·Î ¾Ë·¹¸£±â Áõ»ó(¹ßÁø, ¹ßÀû, °¡·Á¿ò µî)À» ÀÏÀ¸Å² ÀÏÀÌ Àִ ȯÀÚ
2) ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ
3) ³ì³»Àå(´«ÀÇ ÅëÁõ, ´«ÀÇ Ä§Ä§ÇÔ µî) ȯÀÚ, ¹è´¢Àå¾Ö ȯÀÚ(Ç×È÷½ºÅ¸¹ÎÁ¦ ¶Ç´Â ¿°»êµðÆä´Ïµ¹À» ÇÔÀ¯ÇÏ´Â Á¦Á¦)
4) ½ÉÀå¾Ö ȯÀÚ, ³ì³»Àå(´«ÀÇ ÅëÁõ, ´«ÀÇ Ä§Ä§ÇÔ µî) ȯÀÚ, Àü¸³¼± ºñ´ëÁõ ȯÀÚ, Çã¾àÀÚ ¶Ç´Â °í·ÉÀÚ(ºÎ±³°¨½Å°æÂ÷´ÜÁ¦¸¦ ÇÔÀ¯ÇÏ´Â Á¦Á¦)
5) ³ì³»Àå(´«ÀÇ ÅëÁõ, ´«ÀÇ Ä§Ä§ÇÔ µî) ȯÀÚ(¿°»êÆÄÆÄº£¸°À» ÇÔÀ¯ÇÏ´Â Á¦Á¦)
[´Ù¸¸, 3)-5)¿¡ ÇØ´çÇÏ´Â ¼ººÐÀ» µ¿½Ã¿¡ ÇÔÀ¯ÇÏ´Â Á¦Á¦´Â ¸ðµÎ ÇÕÇØ¼ ±âÀçÇÑ´Ù.]
6) ´Ù¸¥ ¾à¹°À» Åõ¿©¹Þ°í Àִ ȯÀÚ
7) °í·ÉÀÚ(ÀϹÝÀûÀ¸·Î °í·ÉÀÚ´Â »ý¸®±â´ÉÀÌ ÀúÇϵǾî ÀÖÀ¸¹Ç·Î °¨·®ÇÏ´Â µî ÁÖÀÇÇÑ´Ù.)
|
| ÀÌ»ó¹ÝÀÀ |
1) ÀÌ ¾àÀ» Åõ¿©ÇÔÀ¸·Î½á ¹ßÁø, ¹ßÀû, °¡·Á¿ò(, ½É°èÇ×Áø) µîÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÏ°í ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÑ´Ù.[( )¾ÈÀº Å©»êƾ°è ¾à¹°À» ÇÔÀ¯ÇÏ´Â Á¦Á¦]
2) ÀÌ ¾àÀ» Åõ¿©ÇÔÀ¸·Î½á ¹è´¢Àå¾Ö µîÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí, ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÑ´Ù(µðÆä´ÒÇǶö¸°¿°·ù, µð¿¤-¸»·¹ÀλêŬ·Î¸£Æä´Ï¶ó¹Î ¶Ç´Â µð-¸»·¹Àλê Ŭ·Î¸£Æä´Ï¶ó¹ÎÀ» ÇÔÀ¯ÇÏ´Â Á¦Á¦).
3) ÀÌ ¾àÀ» Åõ¿©ÇÔÀ¸·Î½á ¹è´¢Àå¾Ö, ´«ºÎ½É, ºÎµ¿°¨, ºÒ¾ÈÁ¤°¨ µîÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ ¿©¸¦ ÁßÁöÇÏ°í ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÑ´Ù(¿°»êµðÆä´Ïµ¹À» ÇÔÀ¯ÇÏ´Â Á¦Á¦).
4) ÀÌ ¾àÀ» Åõ¿©ÇÔÀ¸·Î½á µÎÅë, ¾È¸éÈ«Á¶, ´«ºÎ½É, ¹è´¢°ï¶õ µîÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ ¿©¸¦ ÁßÁöÇÏ°í ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÑ´Ù(ºÎ±³°¨½Å°æÂ÷´ÜÁ¦¸¦ ÇÔÀ¯ÇÏ´Â Á¦Á¦).
5) ÀÌ ¾àÀ» Åõ¿©ÇÔÀ¸·Î½á ±¸°¥, º¯ºñ, ¼³»ç µîÀÌ ³ªÅ¸³ª°í ÀÌ·¯ÇÑ Áõ»óÀÌ Áö¼Ó ¶Ç´Â ¾Ç ȵǴ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÏ°í ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÑ´Ù(¾Æ¹Ì³ë¾È½ÄÇâ»ê¿¡Ä¥ ¶Ç ´Â ÇÇÆä¸®µô¾Æ¼¼Æ¿¾Æ¹Ì³ë¾È½ÄÇâ»ê¿¡Ä¥À» ÇÔÀ¯ÇÏ´Â Á¦Á¦)
[´Ù¸¸, 2)-5)¿¡ ÇØ´çÇÏ´Â ¼ººÐÀ» µ¿½Ã¿¡ ÇÔÀ¯ÇÏ´Â Á¦Á¦´Â 1)-5)¸¦ ÇÕÇØ¼ ±âÀçÇÑ´Ù.]
6) ÀÌ ¾àÀ» Åõ¿©ÇÔÀ¸·Î½á ±¸°¥ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù(Ç×È÷½ºÅ¸¹ÎÁ¦ ¹× ¿°»êµðÆä´Ïµ¹À» ÇÔÀ¯ ÇÏ´Â Á¦Á¦).
7) ÀÌ ¾àÀ» Åõ¿©ÇÔÀ¸·Î½á ±¸°¥ ¶Ç´Â º¯ºñ°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù(ºÎ±³°¨½Å°æÂ÷´ÜÁ¦ ¶Ç´Â ¿° »êÆÄÆÄº£¸°À» ÇÔÀ¯ÇÏ´Â Á¦Á¦).
[´Ù¸¸, 6) ¹× 7)¿¡ ÇØ´çÇÏ´Â ¼ººÐÀ» µ¿½Ã¿¡ ÇÔÀ¯ÇÏ´Â Á¦Á¦¿¡´Â 7)¸¸ ±âÀçÇÑ´Ù.]
|
| »óÈ£ÀÛ¿ë |
´ÙÀ½ ¾àµé°ú º´¿ëÅõ¿©ÇÏÁö ¾Ê´Â´Ù. :
´Ù¸¥ ÁøÅäÁ¦, °¨±â¾à, ÇØ¿ÁøÅëÁ¦, Ç×È÷½ºÅ¸¹ÎÁ¦, ÁøÁ¤Á¦, ÁøÇذŴãÁ¦, À§ÀåÁøÅë‧Áø°æÁ¦ µî
[´Ù¸¸, À§ÀåÁøÅë‧Áø°æÁ¦¿¡ ´ëÇØ¼´Â ºÎ±³°¨½Å°æÂ÷´ÜÁ¦¸¦ ÇÔÀ¯ÇÏ´Â Á¦Á¦¿¡ ÇÑÇÔ]
|
| Off-label Usage |
[Á¶È¸]
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
(meclizine; )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Caffeine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Caffeine stimulates medullary, vagal, vasomotor, and respiratory centers, promoting bradycardia, vasoconstriction, and increased respiratory rate. This action was previously believed to be due primarily to increased intracellular cyclic 3¡Ç,5¡Ç-adenosine monophosphate (cyclic AMP) following inhibition of phosphodiesterase, the enzyme that degrades cyclic AMP. It is now thought that xanthines such as caffeine act as agonists at adenosine-receptors within the plasma membrane of virtually every cell. As adenosine acts as an autocoid, inhibiting the release of neurotransmitters from presynaptic sites but augmenting the actions of norepinephrine or angiotensin, antagonism of adenosine receptors promotes neurotransmitter release. This explains the stimulatory effects of caffeine. Blockade of the adenosine A1 receptor in the heart leads to the accelerated, pronounced "pounding" of the heart upon caffeine intake.
Meclizine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Along with its actions as an antagonist at H1-receptors, meclizine also possesses anticholinergic, central nervous system depressant, and local anesthetic effects. Meclizine depresses labyrinth excitability and vestibular stimulation and may affect the medullary chemoreceptor trigger zone.
Scopolamine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Scopolamine acts by interfering with the transmission of nerve impulses by acetylcholine in the parasympathetic nervous system (specifically the vomiting center).
|
| Pharmacology |
Caffeine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Caffeine, a naturally occurring xanthine derivative like theobromine and the bronchodilator theophylline, is used as a CNS stimulant, mild diuretic, and respiratory stimulant (in neonates with apnea of prematurity). Often combined with analgesics or with ergot alkaloids, caffeine is used to treat migraine and other headache types. Over the counter, caffeine is available to treat drowsiness or mild water-weight gain.
Meclizine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Meclizine, a piperazine-derivative H1-receptor antagonist similar to buclizine, cyclizine, and hydroxyzine, is used as an antivertigo/antiemetic agent. Meclizine is used in the management of nausea, vomiting, and dizziness associated with motion sickness and vertigo in diseases affecting the vestibular apparatus.
Scopolamine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Scopolamine is a muscarinic antagonist structurally similar to the neurotransmitter acetylcholine and acts by blocking the muscarinic acetylcholine receptors and is thus classified as an anticholinergic. Scopolamine has many uses including the prevention of motion sickness. It is not clear how Scopolamine prevents nausea and vomiting due to motion sickness. The vestibular part of the ear is very important for balance. When a person becomes disoriented due to motion, the vestibule sends a signal through nerves to the vomiting center in the brain, and vomiting occurs. Acetylcholine is a chemical that nerves use to transmit messages to each other. It is believe that Scopolamine prevents communication between the nerves of the vestibule and the vomiting center in the brain by blocking the action of acetylcholine. Scopolamine also may work directly on the vomiting center. Scopolamine must be taken before the onset of motion sickness to be effective.
|
| Metabolism |
Caffeine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 1A2 (CYP1A2)
Meclizine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Monoamine oxidase type B (MAO-B)
Scopolamine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Protein Binding |
Caffeine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Low (25 to 36%).
Meclizine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
Scopolamine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Caffeine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 3 to 7 hours in adults, 65 to 130 hours in neonates
Meclizine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 6 hours
Scopolamine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Caffeine¿¡ ´ëÇÑ Absorption Á¤º¸ Readily absorbed after oral or parenteral administration. The peak plasma level for caffeine range from 6-10mg/L and the mean time to reach peak concentration ranged from 30 minutes to 2 hours.
Meclizine¿¡ ´ëÇÑ Absorption Á¤º¸ Well absorbed
Scopolamine¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
Meclizine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- È¿°ú¹ßÇö½Ã°£ : °æ±¸ Åõ¿©½Ã 1½Ã°£ À̳»
- ÀÛ¿ëÁö¼Ó½Ã°£ : 8-24½Ã°£
- ´ë»ç : °£´ë»ç
- ¹Ý°¨±â : 6½Ã°£
- ¼Ò½Ç : ´ë»çü´Â ½Å¹è¼³µÇ°í ´ë»ç¹ÞÁö ¾ÊÀº ¾à¹°Àº º¯À¸·Î ¹è¼³
Scopolamine HBrÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- È¿°ú¹ßÇö½Ã°£
- °æ±¸, ±ÙÀ°ÁÖ»ç : 0.5-1 ½Ã°£
- Á¤¸ÆÁÖ»ç : 10 ºÐ
- È¿°úÁö¼Ó½Ã°£
- °æ±¸, ±ÙÀ°ÁÖ»ç : 4-6 ½Ã°£
- Á¤¸ÆÁÖ»ç : 2 ½Ã°£
- ÃÖ´ëÈ¿°ú ¹ßÇö½Ã°£ : 20-60 ºÐ. Á¤»óÀ¸·Î ¿ÏÀüÈ÷ ȸº¹µÇ´Â µ¥¿¡´Â 3-7ÀÏÀÌ °É¸± ¼ö ÀÖ´Ù.
- Èí¼ö : ¸ðµç Åõ¿©°æ·Î·Î Àß Èí¼öµÈ´Ù.
- ´Ü¹é°áÇÕ : Ç÷Àå´Ü¹é°ú °¡¿ªÀû °áÇÕ
- ´ë»ç : °£´ë»ç
- ¼Ò½Ç : ½Å¹è¼³
Caffeine anhydrousÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : °æ±¸ : ½Å¼ÓÇϰÔ, ¿ÏÀüÈ÷ Èí¼öµÊ (99%)
- ºÐÆ÷ : ¸ðµç ü¾×¿¡ ºÐÆ÷Çϸç, ³úÇ÷°üÀ庮, ŹÝÀ» Åë°úÇϰí, À¯ÁóÀ¸·Îµµ ºÐºñµÊ
- ºÐÆ÷¿ëÀû :
- ½Å»ý¾Æ : 0.92 L/kg
- ¼ºÀÎ : 0.58 L/kg
- ´Ü¹é°áÇÕ : 15-35%
- ´ë»ç : ¼ºÀÎ : °ÅÀÇ ´ëºÎºÐÀÌ °£¿¡¼ ´ë»çµÇ¸ç, Å»¸ÞƿȵǾî paraxanthine (72%), theobromine (20%), theophylline (8%)À¸·Î ´ë»çµÊ
- ¹Ý°¨±â :
- ¹Ì¼÷¾Æ : 65-103 ½Ã°£
- ¿Ï¼÷¾Æ : 82½Ã°£
- 3-4°³¿ù ¿µ¾Æ : 14.4 ½Ã°£
- 5-6°³¿ù ¿µ¾Æ : 2.6 ½Ã°£
- ¼ºÀÎ : 3-7.5 ½Ã°£ (Æò±Õ 4.9 ½Ã°£)
- ÀӽźΠ: 18½Ã°£±îÁö
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : 15-45ºÐ
- ¼Ò½Ç :
- ¼ºÀÎ : ¹Ìº¯Èü·Î ½Å¹è¼³µÇ´Â ¾çÀº 0.5-3.5%
- ½Å»ý¾Æ : °ÅÀÇ ´ëºÎºÐ ¹Ìº¯Èü·Î ½Å¹è¼³µÊ
|
| Biotransformation |
Caffeine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic cytochrome P450 1A2 (CYP 1A2) is involved in caffeine biotransformation. About 80% of a dose of caffeine is metabolized to paraxanthine (1,7-dimethylxanthine), 10% to theobromine (3,7-dimethylxanthine), and 4% to theophylline (1,3-dimethylxanthine).
Scopolamine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Caffeine¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50=127 mg/kg (orally in mice)
Meclizine¿¡ ´ëÇÑ Toxicity Á¤º¸ Symptoms of overdose include drowsiness and anticholinergic effects. LD50=mg/kg (orally in rat).
Scopolamine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Caffeine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
Meclizine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Donepezil Possible antagonism of actionGalantamine Possible antagonism of actionRivastigmine Possible antagonism of action
Scopolamine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Meclizine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take with food to reduce irritation. Avoid alcohol.
|
| Drug Target |
[Drug Target]
|
| SNP Á¤º¸ |
Name:Caffeine (DB00201)
Interacting Gene/Enzyme:Cytochrome P450 1A2 (Gene symbol = CYP1A2) Swissprot P05177
SNP(s):rs762551 (C allele)
Effect:Myocardial infarction
Reference(s):Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H: Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA. 2006 Mar 8;295(10):1135-41. [PubMed]
|
| Description |
Caffeine¿¡ ´ëÇÑ Description Á¤º¸ A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine&
Meclizine¿¡ ´ëÇÑ Description Á¤º¸ A histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness. [PubChem]
Scopolamine¿¡ ´ëÇÑ Description Á¤º¸ An alkaloid from Solanaceae, especially Datura metel L. and Scopola carniolica. Scopolamine and its quaternary derivatives act as antimuscarinics like atropine, but may have more central nervous system effects. Among the many uses are as an anesthetic premedication, in urinary incontinence, in motion sickness, as an antispasmodic, and as a mydriatic and cycloplegic. [PubChem]
|
| Drug Category |
Caffeine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anorexigenic AgentsCentral Nervous System StimulantsPhosphodiesterase Inhibitors
Meclizine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Allergic AgentsAntiemeticsAntihistaminesHistamine H1 Antagonists
Scopolamine¿¡ ´ëÇÑ Drug_Category Á¤º¸ AdjuvantsAdjuvants, AnesthesiaAntimuscarinicsAntispasmodicsCholinergic AntagonistsMuscarinic AntagonistsMydriatics
|
| Smiles String Canonical |
Caffeine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN1C=NC2=C1C(=O)N(C)C(=O)N2C
Meclizine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=CC=C1
Scopolamine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN1C2CC(CC1C1OC21)OC(=O)C(CO)C1=CC=CC=C1
|
| Smiles String Isomeric |
Caffeine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN1C=NC2=C1C(=O)N(C)C(=O)N2C
Meclizine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC1=CC(CN2CCN(CC2)[C@H](C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=CC=C1
Scopolamine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN1[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)C1=CC=CC=C1
|
| InChI Identifier |
Caffeine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3
Meclizine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3
Scopolamine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3
|
| Chemical IUPAC Name |
Caffeine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1,3,7-trimethylpurine-2,6-dione
Meclizine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine
Scopolamine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ Not Available
|
| Drug-Induced Toxicity Related Proteins |
CAFFEINE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Metallothionein Drug:caffeine Toxicity:hepatotoxicity. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-10-13
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|